In October 2017, Ann Beliën founded Rejuvenate Biomed, a spin-off from Johnson and Johnson and currently functions as CEO. Rejuvenate studies the biology of aging and is repurposing prescription drugs with the aim to improve quality of life while aging. Their lead portfolio product focuses on sarcopenia as an entry into the space of healthy aging. Ann has over 18 years of experience in drug development from bench to market, acquired at J&J throughout multiple international assignments from scientist to operational and strategic roles including external and open innovation. She was a postdoc at ETH and holds a PhD from the University of Irchel, Zürich, Switzerland.